Insider Transactions in Q4 2023 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,077
-2.56%
|
$4,077
$1.38 P/Share
|
|
Dec 20
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
13,551
-2.89%
|
$13,551
$1.38 P/Share
|
|
Dec 20
2023
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,990
-3.93%
|
$1,990
$1.38 P/Share
|
|
Dec 20
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
4,077
-3.99%
|
$4,077
$1.38 P/Share
|
|
Dec 20
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,077
-4.5%
|
$4,077
$1.38 P/Share
|
|
Dec 17
2023
|
Lloyd A Rowland General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+9.93%
|
-
|
|
Dec 17
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+11.03%
|
-
|
|
Dec 17
2023
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+7.41%
|
-
|
|
Dec 17
2023
|
Christopher Ogden Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+11.95%
|
-
|
|
Dec 17
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+6.6%
|
-
|